The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA stroke prevention trial.The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor, or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.The move follows an independent safety review that identified increased safety events and evidence that the treatment was unlik ...